Kulik Ulf, Lehner Frank, Bektas Hüseyin, Klempnauer Jürgen
General, Visceral and Transplantation Surgery, Hannover Medical School, Hanover, Germany.
Viszeralmedizin. 2015 Dec;31(6):394-8. doi: 10.1159/000439419. Epub 2015 Nov 24.
Due to the uncertain benefit of liver resection for non-colorectal liver metastases (NCLM), patient selection for surgery is generally difficult. Therefore, the aim of this article was to propose standard and extended indications for liver resection in this heterogeneous disease collective.
Review of the literature.
The myriad of biologically different primary tumor entities as well as the mostly small and retrospective studies investigating the benefit of surgery for NCLM limits the proposal of general recommendations. Only resection of neuroendocrine liver metastases (NELM) appears to offer a clear benefit with a 5- and 10-year overall survival (OS) of 74 and 51%, respectively, in the largest series. Resection of liver metastases from genitourinary primaries might offer reasonable benefit in selected cases - with a 5-year OS of up to 61% for breast cancer and of 38% for renal cell cancer. The long-term outcome following surgery for other entities was remarkably poorer, e.g., gastric cancer, pancreatic cancer, and melanoma reached a 5-year OS of 20-42, 17-25, and about 20%, respectively.
Liver resection for NELM can be defined as a standard indication for the resection of NCLM while lesions of genitourinary origin might be defined as an extended indication.
由于肝切除术治疗非结直肠癌肝转移(NCLM)的获益不确定,手术患者的选择通常很困难。因此,本文的目的是针对这种异质性疾病群体提出肝切除术的标准和扩展适应证。
文献综述。
众多生物学特性不同的原发肿瘤实体,以及大多针对NCLM手术获益的小型回顾性研究,限制了通用建议的提出。在最大规模的系列研究中,仅神经内分泌肝转移瘤(NELM)切除似乎能带来明确获益,5年和10年总生存率(OS)分别为74%和51%。在某些特定病例中,泌尿生殖系统原发肿瘤肝转移灶的切除可能会带来合理的获益——乳腺癌患者5年OS高达61%,肾细胞癌患者为38%。其他实体肿瘤手术后的长期预后明显较差,例如,胃癌、胰腺癌和黑色素瘤患者的5年OS分别为20% - 42%、17% - 25%和约20%。
NELM肝切除术可被定义为NCLM切除的标准适应证,而泌尿生殖系统来源的病灶可被定义为扩展适应证。